Satraplatin

Drug Profile

Satraplatin

Alternative Names: BMS 182751; BMY 45594; JM-216; Orplatna

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Johnson Matthey; The Institute of Cancer Research
  • Developer Agennix AG; Yakult Honsha
  • Class Antineoplastics; Cyclohexylamines; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Squamous cell cancer
  • Phase I Prostate cancer
  • Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 25 May 2016 Yakult Honsha completes a phase-I clinical trial in Prostate cancer (Combination therapy, Hormone refractory, Second-line therapy or greater) in Japan (JapicCTI-080634) prior to May 2016
  • 31 May 2012 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 31 May 2012 Discontinued - Phase-II for Breast cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top